BMEA Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -- compared to Biomea Fusion's net margin of 32.59%. Biomea Fusion's return on equity of -- beat Eli Lilly and's return on equity of 80.24%.

Biomea Fusion has a consensus price target of $23.25, signalling upside risk potential of 910.87%. On the other hand Eli Lilly and has an analysts' consensus of $1,008.64 which suggests that it could grow by 21.61%. Given that Biomea Fusion has higher upside potential than Eli Lilly and, analysts believe Biomea Fusion is more attractive than Eli Lilly and.

Biomea Fusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Biomea Fusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.50 per share. Biomea Fusion pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biomea Fusion quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Biomea Fusion's net income of -$32.8M is lower than Eli Lilly and's net income of $4.4B. Notably, Biomea Fusion's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 70.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion is -- versus 16.65x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Biomea Fusion's net margin of -49.65%. Biomea Fusion's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Biomea Fusion has a consensus price target of $23.25, signalling upside risk potential of 910.87%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 47.26%. Given that Biomea Fusion has higher upside potential than NovaBay Pharmaceuticals, analysts believe Biomea Fusion is more attractive than NovaBay Pharmaceuticals.

Biomea Fusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Biomea Fusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Biomea Fusion quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Biomea Fusion's net income of -$32.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Biomea Fusion's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion is -- versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Biomea Fusion's net margin of --. Biomea Fusion's return on equity of -- beat Palatin Technologies's return on equity of --.

Biomea Fusion has a consensus price target of $23.25, signalling upside risk potential of 910.87%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 3489.74%. Given that Palatin Technologies has higher upside potential than Biomea Fusion, analysts believe Palatin Technologies is more attractive than Biomea Fusion.

Biomea Fusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Biomea Fusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Biomea Fusion quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of --. Biomea Fusion's net income of -$32.8M is higher than Palatin Technologies's net income of --. Notably, Biomea Fusion's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Biomea Fusion's net margin of --. Biomea Fusion's return on equity of -- beat Theriva Biologics's return on equity of --.

Biomea Fusion has a consensus price target of $23.25, signalling upside risk potential of 910.87%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 319.58%. Given that Biomea Fusion has higher upside potential than Theriva Biologics, analysts believe Biomea Fusion is more attractive than Theriva Biologics.

Biomea Fusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

Biomea Fusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Biomea Fusion quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Biomea Fusion's net income of -$32.8M is lower than Theriva Biologics's net income of -$4.4M. Notably, Biomea Fusion's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.